NOTE: For Part 2, click here
Almost one third of US mental health care costs (approximately $50 billion) go toward the treatment of anxiety disorders. Conventional pharmacological treatments for anxiety are often beneficial but have limited efficacy. A meta-analysis of high-quality studies concluded that the efficacy of conventional drug treatments for anxiety disorders varies widely depending on the core symptom being treated.
Phobias, obsessions and compulsions, and symptoms of posttraumatic stress are often poorly responsive to conventional drugs.2 In the context of efficacy and safety issues associated with conventional treatments for anxiety, psychiatrists should know about the evidence for nonconventional therapy. In Part 1 of this article, I review research findings on the most substantiated nonpharmacological and integrative treatments for anxiety. In Part 2, I will discuss less substantiated but promising nonconventional approaches.
Positive research findings consistently support the use of kava and L-theanine in the treatment of persons with generalized anxiety. Regular relaxation, meditation, and mindfulness practices improve symptoms of generalized anxiety, and these nonpharmacological therapies may be safely combined with conventional drugs. Virtual reality graded exposure therapy (VRGET) will play a significant role in the treatment of many anxiety disorders that respond poorly to currently available treatments, such as drugs and cognitive-behavioral therapy (CBT). Numerous studies show that electroencephalographic (EEG) and electromyographic (EMG) biofeedback are as effective as regular relaxation training or mind-body practices for the treatment of moderately severe symptoms of generalized anxiety. A growing body of evidence supports the use of microcurrent stimulation of the CNS for the management of generalized anxiety.
Less-substantiated treatments for anxiety will be reviewed in Part 2 of this column and include dietary changes, supplementation with l-tryptophan or 5-hydroxytryptophan, regular exercise, massage, acupuncture (including electro-acupuncture), healing touch, and Reiki.
VITAMINS AND SUPPLEMENTS
Kava (Piper methysticum)
When kava is used at recommended dosages (typically 60 to 300 mg/d), patients do not experience the mental slowing or impaired cognitive functioning that is typical of many conventional anti-anxiety medications.3 Animal studies suggest that the mechanism of action involves serotonin blockade in the amygdala by alpha-pyrones, a principal bioactive constituent of kava.
Kava also interferes with norepinephrine reuptake and has a high binding affinity with g-aminobutyric acid (GABA) and N-methyl-d-aspartate (NMDA) receptors. Kava may also modulate vagal heart tone in patients with generalized anxiety.4
A systematic review of 11 controlled, double-blind studies that included more than 600 patients concluded that kava was superior to placebo for the short-term management of generalized anxiety.5 Randomized, controlled, double-blind studies support the use of kava preparations that are standardized to 70% kava lactones in divided doses of 70 to 240 mg/d for the treatment of "stress" and moderate anxiety but not for severe anxiety or agitation.6,7 Daily use of standardized kava preparations of 100 to 200 mg was found to effectively reduce anxiety symptoms associated with menopause.8
Kava compares favorably with benzodiazepines and other conventional anti-anxiety drugs. The findings of a small, double-blind, controlled trial suggest that patients who have generalized anxiety who gradually increased their daily dose of kava (up to 300 mg) while tapering off a benzodiazepine did not experience worsening anxiety or benzodiazepine withdrawal.9
A randomized, placebo-controlled, multicenter study of 129 outpatients concluded that a standardized kava preparation (LI 150) was as effective as 2 commonly prescribed anti-anxiety agents (buspirone [BuSpar] and opipramol [Insidon], which is commonly prescribed in Germany) for the treatment of generalized anxiety.10 Three fourths of patients in both the kava group and the conventional drug group experienced 50% or greater reductions in Hamilton Anxiety Scale scores and were classified as "treatment responders."
Kava is generally well tolerated, even at doses significantly above typical therapeutic doses.Uncommon adverse effects include GI upset, rash, headache, and dizziness.11 In recent decades, there have been reports of kava inebriation,12 although this social phenomenon has not been observed in Europe, where kava preparations are used medicinally to treat anxiety. Kava does not potentiate the effects of alcohol consumption in humans. Rare case reports suggest that kava may cross-react with benzodiazepines, increasing their sedating effects.13 Reports of hepatitis14 and fulminant liver failure have led to restrictions in the sale of kava products in many European countries and to a warning issued by the FDA.15 These cases were rare, however, and independent experts have concluded that most reported cases of liver failure were associated with a processing error that resulted in toxic levels of alkaloids in a single batch of kava.16,17
In view of these safety issues, patients should be advised against taking kava18 when there is a question of alcohol abuse or concurrent use of conventional sedative-hypnotics. One case report suggests that kava may interfere with anti-parkinsonian drugs.19
L-Theanine (gamma-ethylamino-L-glutamic acid)
Green tea is used as a restorative in traditional Chinese medicine and contains many bioactive constituents, including the amino acid L-theanine. The anti-anxiety effect of L-theanine is achieved through enhanced alpha brain wave activity and increased synthesis of GABA.20,21 Greater GABA levels, in turn, increase the brain's levels of dopamine and reduce serotonin levels, resulting in general feelings of calm and well-being.22 Changes in brain electrical activity, as measured with EEG, are dose-dependent and are similar to the beneficial EEG changes observed in meditation, including increased alpha waves in the occipital and parietal regions.23 A calming effect is usually noted within 30 to 40 minutes after L-theanine is taken at doses of 50 to 200 mg, and typically lasts 8 to 10 hours. Moderate anxiety symptoms often improve in patients taking 200 mg once or twice daily. More severe anxiety symptoms may require dosages of 600 to 800 mg/d, taken in divided doses of 100 to 200 mg.
Unlike benzodiazepines and other conventional anti-anxiety treatments, L-theanine does not result in increased drowsiness, slowed reflexes, or impaired concentration. There is no risk of tolerance or dependence developing, and there have been no reports of serious adverse effects or interactions with other natural products or conventional drugs.
SOMATIC AND MIND-BODY APPROACHES
Applied relaxation comparable to cognitive therapy
Applied relaxation is a generic term for somatic or mind-body exercises used to diminish generalized anxiety. Relaxation techniques include sustained deep breathing,24 progressive muscle relaxation, guided imagery, and systematic desensitization. Several models have been proposed to explain the anxiety-reducing effects of mind-body practices, including Benson's relaxation response and Selye's general adaptation syndrome. One model posits that anxiety is associated with muscle tension and is reduced by behaviors or cognitions that diminish tension and autonomic arousal. The effectiveness of relaxation as a treatment of various anxiety symptoms has been extensively reviewed.25
Guided imagery is widely used as a self-directed treatment of generalized anxiety. Applied relaxation techniques are often practiced together with mental imagery, meditation, or mindfulness training. Imagery can be individualized to the specific anxiety symptoms of each patient and is known to have beneficial effects on the immune system, physiological stress responses, and cognitive-emotional functioning in general.26 The consistent practice of mental imagery effectively reduces many kinds of anxiety symptoms, including generalized anxiety, feelings of panic, and traumatic memories.27,28 Imagery and relaxation techniques are often used together to induce hypnotic trance states, resulting in a dramatic reduction in symptoms of generalized anxiety.29
In a 5-month prospective study, patients with general anxiety randomized to a relaxation group versus a group treated with conventional antidepressants and relaxation experienced equivalent and significant improvements in state anxiety levels by the end of the trial.30 In a small controlled trial, 36 anxious adult outpatients randomized to 12 weekly sessions of applied relaxation or conventional cognitive therapy experienced significant and comparable reductions in anxiety.31
Combining relaxation with guided imagery is probably more effective than either approach alone. In an open trial, 60 women who reported anxiety and postpartum depression experienced significant reductions in both anxiety and depressed mood using a combined relaxation-guided imagery protocol during the first 4 weeks after childbirth.32 In contrast to the largely beneficial effects of relaxation on general anxiety symptoms, panic attacks are sometimes reported during applied relaxation exercises by those who have panic disorder.33
Open studies and anecdotal evidence provide a strong argument for the therapeutic benefits of regular yoga practice among persons with generalized anxiety. The regular and skillful practice of specific yogic postures or breathing methods results in sustained changes in brain activity and possibly in beneficial changes in neurotransmitter activity that manifest as a subjective state of alert calmness. Training in a particular style called Sudarshan Kriya yoga involves a specialized breathing technique that reportedly decreases serum cortisol levels, the major stress hormone in humans.34 Patients with any anxiety disorder diagnosis improved significantly when they combined a daily yoga practice with relaxation and mindfulness training.35 Yoga reduces anxiety in patients with hypertension and epilepsy,36,37 and probably reduces test anxiety.38 There is some evidence that regular yoga practice reduces the need for conventional drugs in generally anxious patients.37 Findings of a small controlled study showed that the regular practice of a specific Kundalini yoga left-nostril breathing technique significantly reduced symptom severity in patients with obsessive-compulsive disorder.39
1. DiBartolo P, Hofmann S, Barlow D. Psychosocial approaches to panic disorder and agoraphobia: assessment and treatment issues for the primary care physician. Mind/Body Medicine. 1995;1:133-143.
2. Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol. 2001;69:875-899.
3. Russell P, Bakker D, Singh N. The effects of kava on alerting and speed of access of information from long-term memory. Bull Psychonom Soc. 1987;25:236-237.
4. Watkins LL, Connor KM, Davidson JR. Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol. 2001;15:283-286.
5. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383.
6. Singh YN, Blumenthal M. Kava: an overview. HerbalGram: The Journal of the American Botanical Council. 1996;39:33-55. Available at: http://content.herbalgram.org/wholefoodsmarket/herbalgram/articleview.asp?a=126&p=Y. Accessed June 5, 2007.
7. Hansel R. Kava-kava in modern drug research: portrait of a medicinal plant. Zeitschrift Phytother. 1996;17: 180-195.
8. De Leo V, La Marca A, Lanzetta D, et al. Assessment of the association of kava-kava extract and hormone replacement therapy in the treatment of postmenopausal anxiety [in Italian]. Minerva Ginecol. 2000;52:263-267.
9. Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl). 2001;157:277-283.
10. Boerner RJ, Sommer H, Berger W, et al. Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder—an 8-week randomized, double-blind multi-centre clinical trial in 129 out- patients. Phytomedicine. 2003;10:38-49.
11. Schulz V, Hansel R, Tyler V. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 4th ed. Berlin: Springer; 2001.
12. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust. 1988;148:548-555.
13. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava kava and alprazolam. Ann Intern Med. 1996;125:940-941.
14. Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ. 2001;322:139.
15. Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant kava-kava [in German]. Dtsch Med Wochenschr. 2001; 126:970-972.
16.Waller D. DABT's review of adverse events reportedly associated with kava. Silver Spring, Md: American Herbal Products Association; February 15, 2002.
17. Dragull K, Yoshida WY, Tang CS. Piperidine alkaloids from Piper methysticum. Phytochemistry. 2003;63: 193-198.
18. Bone K. Kava: a safe herbal treatment for anxiety. Br J Phytother. 1994;3:147-153.
19. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163-2175.
20. Juneja LR, Chu DC, Okubo T, et al. L-theanine—a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Tech. 1999;10:199-204.
21. Kakuda T, Nozawa A, Unno T, et al. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci Biotechnol Biochem. 2000;64:287-293.
22. Mason R. 200 mg of Zen: L-theanine boosts alpha waves, promotes alert relaxation. Alternative & Complementary Therapies. 2001;7:91-95.
23. Ito K, Nagato Y, Aoi N, et al. Effects of L-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi. 1998;72:153-157.
24. Davis M, McKay M, Eshelman E. The Relaxation and Stress Reduction Workbook. 2nd ed. Oakland, Calif: New Harbinger Press; 1982.
25. Titlebaum H. Relaxation. Alternative Health Practitioner. 1998;4:123-146.
26. Achterberg J. Imagery in Healing: Shamanism and Modern Medicine. Boston: New Science Library; 1985.
27. Zahourek R. Imagery. Alternative Health Practitioner. 1998;4:203-231.
28. Achterberg J, Dossey B, Kolkmeier L. Rituals of Healing: Using Imagery for Health and Wellness. New York: Bantam Books; 1994.
29. Spiegel H, Spiegel D. Trance and Treatment: Clinical Uses of Hypnoses. New York: Basic Books; 1978:22-23.
30. Bernal C, Fuste VR, Urbieta SR, Montesinos MI. Relaxation therapy in patients with anxiety and somatoform disorders in primary care [in Spanish]. Atencion Primaria. 1995;15:499-504.
31. Ost LG, Breitholtz E. Applied relaxation vs cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther. 2000;38:777-790.
32. Rees BL. Effect of relaxation with guided imagery on anxiety, depression, and self-esteem in primiparas. J Holist Nurs. 1995;13:255-267.
33. Knott V, Bakish D, Lusk S, Barkely J. Relaxation- induced EEG alterations in panic disorder patients. J Anxiety Disord. 1997;11:365-376.
34. Gangadhar BN, Janakiramaiah N, Sudarshan B, et al. Stress-related biochemical effects of Sudarshan Kriya Yoga in depressed patients, study 6. Presented at: the Conference on Biological Psychiatry, UN NGO Mental Health Committee; May 2000; New York.
35. Miller JJ, Fletcher K, Kabat-Zinn J. Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen Hosp Psychiatry. 1995;17: 192-200.
36. Panjwani U, Gupta HL, Singh SH, et al. Effect of Sahaja yoga practice on stress management in patients of epilepsy. Indian J Physiol Pharmacol. 1995;39:111-116.
37. Chaudhary AK, Bhatnagar HN, Bhatnagar LK, et al. Comparative study of the effect of drugs and relaxation exercise (yoga Shavasan) in hypertension. J Assoc Physicians India. 1988;36:721-723.
38. Malathi A, Damodaran A. Stress due to exams in medical students--role of yoga. Indian J Physiol Pharmacol. 1999;43:218-224.
39. Shannahoff-Khalsa DS, Ray LE, Levine S, et al. Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder. CNS Spectr. 1999;4:34-47.
40. Delmonte MM. Meditation and anxiety reduction: a literature review. Clin Psychol Rev. 1985;5:91-102.
41. Kabat-Zinn J, Borysenko J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. New York: Delacorte Press; 1990.
42. Kabat-Zinn J, Massion AO, Kristeller J, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992;149:936-943.
43. Abbey S. Mindfulness-based stress reduction groups. Presented at: Annual meeting of the American Psychiatric Association; May 2004; New York. Abstract 72C.
44. Keefer L, Blanchard E. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behav Res Ther. 2001;39:801-811.
45. Epstein R. Mindful practice. JAMA. 1999;282: 833-839.
46. Pertaub D, Slater M, Barker C. An experiment on fear of public speaking in virtual reality. In:Westwood J, Hoffman H, Mogel G, Stredney D, eds. Medicine Meets Virtual Reality. Vol 81. Amsterdam: IOS Press; 2001.
47. Emmelkamp P, Bruynzeel M, Drost L, et al. Virtual reality treatment in acrophobia: a comparison with exposure in vivo. Cyberpsychol Behav. 2001;4:335-339.
48. Vincelli M, Choi Y, Molinari E, et al. Experiential cognitive therapy for the treatment of panic disorder with agoraphobia: definition of a protocol. Cyberpsychol Behav. 2000;3:375-385.
49. Riva G, Alcaniz A, Anolli L, et al. The VESPY updated project: virtual environments in clinical psychology. Cyberpsychol Behav. 2001;4:449-455.
50. Vincelli F, Anolli L, Bouchard S, et al. Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: a controlled study. Cyberpsychol Behav. 2003;6:321-328.
51. Rothbaum B, Smith S, Hodges L, Lee J. A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000;68:1020-1026.
52. Wiederhold BK, Jang DP, Gevirtz RG, et al. The treatment of fear of flying: a controlled study of imaginal and virtual reality graded exposure therapy. IEEE Trans Inf Technol Biomed. 2002;6:218-223.
53. Rothbaum B, Hodges L, Smith S. Virtual reality exposure therapy abbreviated treatment manual: fear of flying application. Cog Behav Pract. 1999;6:234-244.
54. Rothbaum BO, Hodges LF. The use of virtual reality exposure in the treatment of anxiety disorders. Behav Modif. 1999;23:507-525.
55. Glantz K, Durlach N, Barnett R, Aviles W. Virtual reality for psychotherapy: from the physical to the social environment. Psychotherapy. 1996;33:464-473.
56. Maltby N, Kirsch I, Mayers M, Allen GJ. Virtual reality exposure therapy for the treatment of fear of flying: a controlled investigation. J Consult Clin Psychol. 2002;70: 1112-1118.
57. Difede J, Hoffman H. Virtual reality exposure therapy for World Trade Center post-traumatic stress disorder: a case report. Cyberpsychol Behav. 2002;5:529-535.
58. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002; 22:2343-2351.
59. Ressler K, Rothbaum B, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136-1144.
60. Botella C, Banos R, Guillen V, et al. Telepsychology: public speaking fear treatment on the Internet. Cyberpsychol Behav. 2000;3:959-968.
61. Wiederhold B, Wiederhold M. Side effects and contraindications. In: Virtual Reality Therapy for Anxiety Disorders: Advances in Evaluation and Treatment. Washington, DC: American Psychological Press; 2005.
62. Hurley JD, Meminger SR. A relapse-prevention program: effects of electromyographic training on high and low levels of state and trait anxiety. Percept Mot Skills. 1992;74:699-705.
63. Wenck LS, Leu PW, D'Amato RC. Evaluating the efficacy of a biofeedback intervention to reduce children's anxiety. J Clin Psychol. 1996;52:469-473.
64. Vanathy S, Sharma PS, Kumar KB. The efficacy of alpha and theta neurofeedback training in treatment of generalized anxiety disorder. Indian J Clin Psychol. 1998; 25:136-143.
65. Rice KM, Blanchard EB, Purcell M. Biofeedback treatments of generalized anxiety disorder: preliminary results. Biofeedback Self Regul. 1993;18:93-105.
66. Sarkar P, Rathee SP, Neera N. Comparative efficacy of pharmacotherapy and bio-feedback among cases of generalised anxiety disorder. J Projective Psychol Ment Health. 1999;6:69-77.
67. Ossebaard HC. Stress reduction by technology? An experimental study into the effects of brainmachines on burnout and state anxiety. Appl Psychophysiol Biofeedback. 2000;25:93-101.
68. Schroeder MJ, Barr RE. Quantitative analysis of the electroencephalogram during cranial electrotherapy stimulation. Clin Neurophysiol. 2001;112:2075-2083.
69. Klawansky S, Yeung A, Berkey C, et al. Meta-analysis of randomized controlled trials of cranial electrostimulation: efficacy in treating selected psychological and physiological conditions. J Nerv Ment Dis. 1995;183: 478-484.
70. DeFelice E. Cranial electrotherapy stimulation (CES) in the treatment of anxiety and other stress-related disorders: a review of controlled clinical trials. Stress Med. 1997;13:31-42.
71. Overcash S. A retrospective study to determine the effect of cranial electrotherapy stimulation (CES) on patients suffering from anxiety disorders. Am J Electromed. 1999;16:49-51.
72. Heffernan M. The effect of a single cranial electrotherapy stimulation on multiple stress measures. The Townsend Letter for Doctors and Patients. 1995;147: 60-64.
73. Smith R, Shiromoto F. The use of cranial electrotherapy stimulation to block fear perception in phobic patients. J Curr Ther Res. 1992;51:249-253.